Relay Therapeutics Reports Revenue Growth, Narrower Loss, and FDA Breakthrough for Zovegalisib

Relay Therapeutics, Inc. reported full-year 2025 results with revenue rising to $15.36 million from $10.01 million and its net loss narrowing to $276.48 million from $337.71 million, while also securing FDA Breakthrough Therapy designation for lead asset zovegalisib. Basic loss per share narrowed to $1.61 versus $2.36 a year earlier.

The company filed a $96.18 million common-stock shelf registration tied to an ESOP offering. The Breakthrough Therapy designation and packed 2026 data calendar pull clinical outcomes for zovegalisib closer to center stage.

Zovegalisib is the first pan-mutant selective PI3Kα inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Kα-driven vascular anomalies.

Relay Therapeutics is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. The company's Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed.

The company's pipeline also includes programs for NRAS-driven solid tumors and Fabry disease. Relay Therapeutics is headquartered in Cambridge, Massachusetts and was founded in 2016.

Management will participate in two upcoming fireside chats in March: the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 3:10 p.m. ET and the Barclays 28th Annual Global Healthcare Conference on Wednesday, March 11, 2026 at 10:30 a.m. ET.

Shares of Relay Therapeutics have been given an average rating of "Moderate Buy" by eight ratings firms. One research analyst has rated the stock with a sell recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $16.5714.

The CFO sold 13,820 shares in a transaction dated Tuesday, January 27th at an average price of $7.62, for a total value of $105,308.40. Following the completion of the sale, the chief financial officer owned 250,996 shares of the company's stock, valued at approximately $1,912,589.52. Another insider sold 18,895 shares in a transaction that occurred on Tuesday, January 27th at an average price of $7.62, for a total value of $143,979.90.

Shares of Relay Therapeutics opened at $8.93 on Friday. The company has a fifty-two week low of $1.77 and a fifty-two week high of $9.54. The company's 200-day moving average is $6.34. The company has a market capitalization of $1.55 billion, a P/E ratio of -5.10 and a beta of 1.59. 96.98% of the stock is currently owned by institutional investors.